PHASE-I TRIAL OF RECOMBINANT INTERFERON-GAMMA IN CANCER-PATIENTS

被引：144

作者：

VADHANRAJ, S

ALKATIB, A

BHALLA, R

PELUS, L

NATHAN, CF

SHERWIN, SA

OETTGEN, HF

KROWN, SE

机构：

[1] MEM SLOAN KETTERING CANC CTR,DEPT MED,CLIN IMMUNOL SERV,1275 YORK AVE,NEW YORK,NY 10021

[2] MEM SLOAN KETTERING CANC CTR,LYMPHOCYTE SURFACE MARKERS LAB,NEW YORK,NY 10021

[3] MEM SLOAN KETTERING CANC CTR,DEPT CLIN CHEM,NEW YORK,NY 10021

[4] MEM SLOAN KETTERING CANC CTR,DEV HEMATOPIESIS LAB,NEW YORK,NY 10021

[5] ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021

[6] GENENTECH INC,SAN FRANCISCO,CA 94080

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1986年 / 4卷 / 02期

关键词：

D O I：

10.1200/JCO.1986.4.2.137

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：137 / 146

页数：10

共 45 条

[1]

ALKATIB A, 1984, P AM ASSOC CANC RES, V25, P235

[2]

ALKATIB A, 1985, P AM ASSOC CANC RES, V26, P275

[3]

BASHAM TY, 1983, J IMMUNOL, V130, P1492

[4] PURIFIED HUMAN IMMUNE INTERFERON HAS MORE POTENT ANTICELLULAR ACTIVITY THAN FIBROBLAST OR LEUKOCYTE INTERFERON [J].

BLALOCK, JE ;

GEORGIADES, JA ;

LANGFORD, MP ;

JOHNSON, HM .

CELLULAR IMMUNOLOGY, 1980, 49 (02) :390-394

[5]

BOCCI V, 1982, J GEN VIROL, V60, P297

[6]

BORDEN EC, 1981, PROG HEMATOL, V12, P299

[7] EVIDENCE THAT TYPE-I AND TYPE-II INTERFERONS HAVE DIFFERENT RECEPTORS [J].

BRANCA, AA ;

BAGLIONI, C .

NATURE, 1981, 294 (5843) :768-770

[8]

CRANE JL, 1978, J NATL CANCER I, V61, P871

[9] SYNERGISTIC ANTIVIRAL AND ANTIPROLIFERATIVE ACTIVITIES OF ESCHERICHIA-COLI-DERIVED HUMAN ALPHA-INTERFERON, BETA-INTERFERON, AND GAMMA-INTERFERON [J].

CZARNIECKI, CW ;

FENNIE, CW ;

POWERS, DB ;

ESTELL, DA .

JOURNAL OF VIROLOGY, 1984, 49 (02) :490-496

[10]

DIANZANI F, 1978, P SOC EXP BIOL MED, V159, P94

← 1 2 3 4 5 →